Clinical Trials Browser

Phase 1 × Everolimus × Tumor-Agnostic × Clear all

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT02123823 2025-07-15

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Phase 1 Completed

164 enrolled 21 charts

Neoplasms

NCT01197170 2021-01-22

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

Phase 1 Completed

Neoplasm Metastasis

NCT01122199 2017-05-10

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasm Metastasis

NCT00985374 2016-11-02

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Phase 1 Terminated

Neoplasms

NCT01096199 2014-01-22

A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)

Phase 1 Terminated

Neoplasms

NCT01932177 2013-08-30

EVESOR

Phase 1 Unknown

Neoplasm Metastasis

NCT00496600 2012-06-14

Phase I Study of Patupilone and RAD001

Phase 1 Completed

Neoplasms